Core Insights - LIXTE Biotechnology Holdings, Inc. announced the online publication of pre-clinical data demonstrating the conversion of its lead compound LB-100 into the active form endothall, which is effective in cancer treatment when combined with immunotherapy [1][4] - The discovery of an enzyme that mediates this conversion could serve as a potential biomarker to identify patients likely to respond to LB-100 [2] - Clinical trials for LB-100 are currently underway for ovarian and colorectal cancer, with the new data aiding in optimizing patient selection for future trials [4] Group 1: Scientific Findings - The Netherlands Cancer Institute identified an enzyme that facilitates the conversion of LB-100 into endothall, suggesting its role as a potential biomarker [2] - Research from BioPharmaWorks LLC indicates that LB-100 converts into endothall through hydrolysis, although this process is slow under physiological conditions [3] Group 2: Company Overview - LIXTE is focused on developing new cancer therapies, with LB-100 being a first-in-class PP2A inhibitor that has shown good tolerance in cancer patients [4] - The company claims that LB-100 has the potential to improve outcomes for patients undergoing various chemotherapies or immunotherapies, supported by a comprehensive patent portfolio [4]
New Findings Show how LIXTE's Lead Clinical Compound, LB-100, is Metabolized to its Active Form